Qiu Yajuan, Zhou Zhiyuan, Li Zhaoming, Lu Lisha, Li Ling, Li Xin, Wang Xinhua, Zhang Mingzhi
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Proteomics Clin Appl. 2017 Mar;11(3-4). doi: 10.1002/prca.201600111. Epub 2016 Dec 7.
The aim of the present study was to identify the potential relevant biomarkers to predict the therapeutic response of advanced extranodal natural killer/T cell lymphoma(ENKTL) treated with asparaginase-based treatment.
Proteomic technology is used to identify differentially expressed proteins between chemotherapy-resistant and chemotherapy-sensitive patients. Then enzyme-linked immunosorbent assay is used to validate the predictive value of selective biomarkers.
A total of 61 upregulated and 22 downregulated proteins are identified in chemotherapy-resistant patients compared with chemotherapy-sensitive patients. Furthermore, they validated that pretreatment high level 14-3-3 epsilon(ε)(≥61.95 ng/mL, 84.0 and 95.2% for sensitivity and specificity, respectively) is associated with poor 2-year overall survival (OS) (5.3 vs 68.8%, p<0.0001) and PFS (4.5 vs 76.9%, p<0.0001). In multivariate survival analysis, pretreatment high level 14-3-3 epsilon significantly is correlated with both inferior OS (p = 0.033) and PFS (p = 0.005).
These findings indicate that pretreatment high level 14-3-3 epsilon is an independent predictor of chemotherapy-resistance and poor prognosis for patients with advanced ENKTL in the era of asparaginase.
本研究旨在确定潜在的相关生物标志物，以预测接受基于天冬酰胺酶治疗的晚期结外自然杀伤/T细胞淋巴瘤（ENKTL）的治疗反应。
采用蛋白质组学技术鉴定化疗耐药和化疗敏感患者之间差异表达的蛋白质。然后使用酶联免疫吸附测定法验证选择性生物标志物的预测价值。
与化疗敏感患者相比，在化疗耐药患者中总共鉴定出61种上调蛋白和22种下调蛋白。此外，他们验证了预处理时高水平的14-3-3ε（≥61.95 ng/mL，敏感性和特异性分别为84.0%和95.2%）与2年总生存期（OS）较差（5.3%对68.8%，p<0.0001）和无进展生存期（PFS）较差（4.5%对76.9%，p<0.0001）相关。在多因素生存分析中，预处理时高水平的14-3-3ε与较差的OS（p = 0.033）和PFS（p = 0.005）均显著相关。
这些发现表明，在天冬酰胺酶治疗时代，预处理时高水平的14-3-3ε是晚期ENKTL患者化疗耐药和预后不良的独立预测指标。
Zotero 插件